Sanofi Aventis laboratories indicate that the summary of the characteristics of Acomplia (rimonabant), the anti-obesity pill sold in France since March 2007 has been changed…

This statement now includes new warnings and recommendations for monitoring during treatment. This drug carries the risk of depressive disorders in early treatment. The recommendations were prepared with Afssaps and EMEA.

Acomplia is indicated for the treatment of obese people, that is to say whose body mass index, calculated by dividing weight (in kilograms) by height (in meters) squared, exceeds 30. People in very overweight with associated risk factors such as type 2 diabetes or dyslipidemia, may also be prescribed the drug. Only those with obesity and type 2 diabetes are affected by reimbursement of the drug, available only on prescription.

Rimonabant, processing new generation’s role is to reduce weight and waist circumference, but also improve glucose and lipid metabolism, and thus the fight against diabetes. In France, since its authorization in the market in March 2007, 160,000 patients have been treated with Acomplia. 988 cases of adverse reactions have been confirmed, including 250 serious.

Interested in the latest automotive news, find exceptional cars, used car or info on tuning. Also find the latest information: science news, science news for Junior, the news people, the news of the stars of the TV, the box-office movies or the theater box office at Paris or science for juniors. Lastly ladies, discover the trends of fashion, and then after the full desires of our senior Portal, find advice wellness, recreation or creative style advice beauty. And gentlemen, if you find your happiness by viewing the TV program or TV guide, you can always go to the Hunt.


.